Loading...
Projects / Programmes source: ARIS

Prognostic and predictive factors for response in treatment of different types of cancer

Periods
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 

Code Science Field
3.02  Medical and Health Sciences  Clinical medicine 
Keywords
sequencing of the new generation, liquide biopsy, predictive and prognostic factors, predictive response factor for treatment, different types of cancer
Evaluation (rules)
source: COBISS
Points
5,540.49
A''
255.03
A'
1,179.24
A1/2
2,208.43
CI10
17,772
CImax
2,178
h10
51
A1
17.21
A3
28.27
Data for the last 5 years (citations for the last 10 years) on July 13, 2024; A3 for period 2018-2022
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  677  17,881  17,323  25.59 
Scopus  563  20,513  19,926  35.39 
Researchers (25)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  14114  PhD Darja Arko  Oncology  Researcher  2020 - 2024  324 
2.  58264  Maša Auprih  Oncology  Junior researcher  2023 - 2024  19 
3.  16303  PhD Simona Borštnar  Oncology  Researcher  2020 - 2024  502 
4.  20133  Nina Čas Sikošek  Oncology  Technical associate  2020 - 2024  85 
5.  53393  Eva Erzar  Medical sciences  Junior researcher  2020 - 2024 
6.  32509  Kristina Gornik Kramberger  Oncology  Technical associate  2021 - 2024  42 
7.  15875  PhD Cvetka Grašič Kuhar  Oncology  Researcher  2020 - 2024  261 
8.  12022  PhD Barbara Jezeršek Novaković  Oncology  Researcher  2020 - 2024  333 
9.  10772  PhD Rajko Kavalar  Oncology  Researcher  2020  253 
10.  12224  PhD Borut Kragelj  Oncology  Retired researcher  2020 - 2024  81 
11.  51959  PhD Damjan Manevski  Public health (occupational safety)  Researcher  2022 - 2023  42 
12.  34225  PhD Tanja Marinko  Medical sciences  Researcher  2020 - 2024  167 
13.  20055  PhD Erika Matos  Oncology  Researcher  2020 - 2024  197 
14.  32614  PhD Tanja Mesti  Medical sciences  Researcher  2020 - 2024  198 
15.  51035  Milena Mikluš  Oncology  Technical associate  2021 
16.  13541  PhD Janja Ocvirk  Oncology  Head  2020 - 2024  831 
17.  54719  Matej Panjan  Medical sciences  Junior researcher  2020 - 2024 
18.  55823  Tina Pavlin  Oncology  Junior researcher  2021 - 2024 
19.  51964  PhD Jakob Peterlin  Mathematics  Researcher  2023  10 
20.  20056  PhD Martina Reberšek  Oncology  Researcher  2020 - 2024  264 
21.  33230  PhD Nina Ružić Gorenjec  Mathematics  Researcher  2020 - 2021  52 
22.  24577  PhD Boštjan Šeruga  Medical sciences  Researcher  2020 - 2024  310 
23.  01324  PhD Iztok Takač  Human reproduction  Researcher  2020 - 2024  917 
24.  52993  Aljaž Valič  Sport  Technical associate  2021 - 2024  20 
25.  11747  PhD Branko Zakotnik  Oncology  Retired researcher  2020 - 2021  425 
Organisations (3)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,816 
2.  0334  University Medical Centre Maribor  Maribor  5054150000  23,077 
3.  0381  University of Ljubljana, Faculty of Medicine  Ljubljana  1627066  48,704 
Abstract
At the Institute of Oncology Ljubljana are treated patients with different types of tumors, using also the new treatment modalities, including targeted drugs and immunotherapy. This research program will continue to explore already established and develop new prognostic and predictive factors that can predict the response to the treatment. This will help us in finding the best personalized approach to every patient and offer the optimal treatment to each individual cancer patient. Knowing the biomarkers status in patients with various cancers can give us information about the course of the disease and the response to the treatment. Early discovery of a disease recidive or progression enables oncologists for early treatment and therapeutic strategy change when we can catch the disease while in a smaller scale and the patient in a better condition. Consequently a longer survival of the patient will be achieved. For this aim, genetic analyzes of cancerous tissue and / or body liquids assessed with next generation sequencing will be incorporated. Sequencing of target genes can determine various genetic changes or mutations, and change of the molecular profile of the disease in the course of the treatment or in the case of disease progression. Different gene mutations are more typical for certain cancers and their treatment, and they also show the different organic affinity of cancer cells for breeding. The next generation sequencing is a new tool, already validated and highly sensitive to detect the changes in the dynamics of the disease or changes in the molecular profile of the disease very early and can provide data for the simultaneous detection and identification of fusions, point mutations, and the expression level of more than hundred genes specific to different cancers. Here we will develop some new potential biomarkers that can predict the affinity of the cancer cells for breading, like the presence of gene mutations for Tropomyosin receptor kinase (NTRK1, NTRK2, NTRK3) that indicate affinity for the brain, with a poor prognosis or high expression of interferon alpha (IFN) genes, assessed by Interferon Gamma Messenger RNA Signature, that can be a predictive factor for a better response to immunotherapy (PD1 / PDL1 inhibitors). New knowledge and new tumor biomarkers will be eventually implemented in treatment of cancer patients in Slovenia.
Significance for science
Due to better understanding of the biology of cancer many new effective anticancer agents were approved in recent years. In oncology we strive for the personalized approach. With this approach we aim to treat every individual cancer patient with the most effective and at the same time the least toxic therapy. To reach this goal it is important to know prognostic factors and predictive factors for response to a particular anticancer therapy. Furthermore, it is also important to understand predictive factors for for the development of early and late toxic effects related to anticancer treatment. The biggest advancement in treatment of cancer are targeted agents and the immunotherapy. These drugs are the most effective in cancers with dominant signalling pathways, which are crucial for growth of tumor (e.g. cetuximab targeting EGFR in EGFR positive metastatic colorectal cancer, trastuzumab targeting HER-2 in HER-2 positive breast cancer, imatinib targeting Bcr-Abl fusion protein in chronic myeloic leukemia or gefitinib targeting the activating mutation of EGFR in non-small cell lung cancer). In these cancers biomarkers are available, which predict response to these agents. Unfortunatelly, not all targeted agents are like this. Although they are called targeted agents for many of them actually we do not know the corresponding targets within cancer cells or they are targeting pathways which are not dominant. Consequently, there are no predictive biomarkers available for them. An examplele of such drugs are mTOR inhibitors, which are used for treatment of patients with advanced renal cell carcinoma or VEGF inhibitors used in advanced colorectal cancer. Before the start of therapy with mTOR or VEGF inhibitors we cannot predict which patients will benefit from these drugs. However, most of the patients who receive these drugs develop toxic effects, some life-threatening side effects.Therefore, it is of paramount importance to identify predictive biomarkers for response to these and other similar drugs. We also need to identify new prognostic biomarkers (e.g. NTRK1, NTRK2, NTRK3 ), which could potentially serve as targets for the development of new and more effective therapies, and in the same time can predict the cancer cells breeding afinity for different organs, esspecially for the CNS. Interferon Gamma Messenger RNA Signature is a predictive factor for a better response to immunotherapy (PD1 / PDL1 inhibitors). Increased intensity of interferon alpha (IFN) genes can be determined by IFN signature - Interferon Gamma Messenger RNA Signature. Early discovery of a disease recidive or progression enables oncologists for early treatment and therapeutic strategy change when we can catch the disease while in a smaller scale and the patient in a better condition. Consequently a longer survival of the patient should be acchieved. Genetic analyzes of cancerous tissue and / or body liquids with the next generation sequencing, can predict changes in the dynamics of the disease or changes in the molecular profile of the disease very early. The burden of circulating tumor DNA (cDNA) is an early negative predictive factor. Sequencing of target genes can determine various genetic changes or mutations, and change of the molecular profile of the disease in the course of treatment or in the case of disease progression. Different gene mutations are more typical for certain cancers and their treatment, and they also show the different organic affinity of cancer cells for breeding.
Significance for the country
The goal of the contemporary oncologic treatment is thepersonalized approach, which allows every individual patient the most effective and at the same time the least toxic treatment. With better understanding of prognostic and predictive factors we can further improve currently available personalized approach. In an individual patient we aim to improve a chance of cure and to minimize acute and chronic toxic effects of therapy. A higher proportion of cured patients who experience minimal late side effects of treatment could contribute to increased power of our State. Not only an individual but the whole community can benefit by this approach. The average monthly cost of new anticancer systemic therapies for an individual patient is several thousand of euros. However, many patients who are treated with these new agents do not benefit from them. In current situation of the economic crisis costs of anticancer treatment are becoming unsustainable. With better tailored personalized treatment approach we could substantially decrease the costs of oncologic treatment.   Results of our studies will be published in international journals and presented at interanational scientific meetings, which can increase the visibility of Slovenia around the world. Our research studies will enable even more intensive integration of Slovenian researchers into the interantional scientific community. In Slovenia, our research program will contribute fo a faster introduction of modern methods in routine practice and to improved professional quality. During program implementation we will ensure education and training of students and other people in training.
Views history
Favourite